Name: NOVO NORDISK A/S-B (NOV) Stock
Brand: NOVO NORDISK A/S-B
Rating: 5 (3 reviews)

Question 1

What does NOV do?

Accepted Answer

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Question 2

What is the current price of NOV stock?

Accepted Answer

The current stock price of NOV.DE is 44.415 EUR. The price increased by 9.13% in the last trading session.

Question 3

Does NOV stock pay dividends?

Accepted Answer

NOVO NORDISK A/S-B (NOV.DE) has a dividend yield of 3.83%. The yearly dividend amount is currently 1.33.

Question 4

What is the ChartMill technical and fundamental rating of NOV stock?

Accepted Answer

NOV.DE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 7 out of 10.

Question 5

What is NOVO NORDISK A/S-B worth?

Accepted Answer

NOVO NORDISK A/S-B (NOV.DE) has a market capitalization of 197.36B EUR. This makes NOV.DE a Large Cap stock.

NOVO NORDISK A/S-B (NOV.DE) Stock Price, Forecast & Analysis

NOV.DE Latest News, Press Relases and Analysis